Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Luminal-type breast cancer (BC) was characterized as hormonal receptor positive human epidermal receptor 2 negative (HR+/HER2-), which comprises the majority of breast cancer (BC). The 70-gene signature (70-GS, MammaPrint) test is recommended for assessing recurrence risk and guiding adjuvant chemotherapy decisions in Luminal-type BC. Based on our previously established nomogram models for predicting binary categorized risk of 70-GS, this study aims to update nomogram models to predict binary 70-GS risk for lymph node positive (LN+) and lymph node negative (LN-) luminal-type BC patients. Methods: This retrospective study included 301 consecutive female patients with HR+/HER2- BC treated at Peking Union Medical College Hospital from November 2019 to December 2023. Patients' medical history, imaging reports, and clinicopathological features were reviewed. Forty risk parameters were compared between 70-GS high vs. low-risk patients among LN+ and LN- groups. High risk stratification criterion in MonarchE and Natalee were compared between low and high 70-GS risk for the first time. Logistic regression was utilized to establish nomogram models predicting binary 70-GS risk for LN+ and LN- patients. The models' prediction performance was evaluated using accuracy, AUC of ROC curves, C-index, calibration curves, and decision curve analysis. Results: Significant differences were found in several risk parameters between 70-GS high vs. low-risk patients in both LN+ and LN- groups. Among LN+ patients, parameters including childbirth number (p=0.024), cardiovascular diseases (p=0.037), US min. diameter of tumor (p=0.034), Ki67 index (p<0.001) and PR positivity (p=0.007) were significant predictors. Among LN- patients, micro-calcifications (p=0.011), PR positivity (p=0.021), and Ki67 index (p<0.001) were significant. The nomogram models showed high predictive accuracy, with AUC of 0.948 in the training set (C-index 0.948, 0.914-0.982, accuracy 0.907) and 0.923 in the testing set (C-index 0.923, 0.919-0.927, accuracy 0.828) for LN+ patients and 0.917 in the training set (C-index 0917, 0.861-0.972, accuracy 0.870) and 0.917 in the testing sets (C-index 0917, 0.912-0.922, accuracy 0.808) among LN- patients. Calibration plots and decision curve analysis demonstrated the models' reliability and clinical utility. Conclusions: Our updated nomogram models for predicting 70-GS risk in LN+ and LN- luminal-type BC patients demonstrated improved prediction performance. The models facilitate individualized risk assessment and treatment decision-making, highlighting the distinct risk factor distributions between LN+ and LN- patients. These findings support the use of tailored approaches in managing luminal-type BC based on lymph node status.

Article activity feed